

C-terminal amino acid determination of the transmembrane subunits of the human platelet fibrinogen receptor, the GPIIb/IIIa complex

J.J. Calvete⁺*, W. Schäfer⁺, A. Henschen⁺ and J. Gonzalez-Rodriguez*

⁺Max-Planck-Institut für Biochemie, 8033 Martinsried, FRG and *Instituto de Química-Física, CSIC, c/Serrano, 119, 28006 Madrid, Spain

Received 4 January 1990; revised version received 13 February 1990

Glycoproteins IIb (GPIIb) and IIIa (GPIIIa) form the Ca^{2+} -dependent GPIIb/IIIa complex, which acts as the fibrinogen receptor on activated platelets. GPIIb and GPIIIa are synthesized as single peptide chains. The GPIIb precursor is processed proteolytically to yield two disulphide-bonded chains, GPIIb α and GPIIb β . The GPIIb/IIIa complex has two membrane attachment sites located at the C-termini of GPIIb β and GPIIIa. The short cytoplasmic tails of GPIIb β and/or GPIIIa become most likely associated to the cytoskeleton of activated platelets. In the present work the C-terminal amino acid residues of platelet GPIIb β and GPIIIa have been analyzed by protein-chemical methods and compared with those predicted from cDNA analysis. We were able to confirm the positions of the C-termini in both glycoproteins and the identity of the C-terminus predicted for GPIIIa, i.e. threonine. However, glutamine, not glutamic acid as predicted for GPIIb β from the human erythroleukemic cell line and megakaryocyte cells, was found to be the C-terminal amino acid of GPIIb β . This indicates that the glutamic acid in the GPIIb precursor is posttranslationally modified to glutamine.

Platelet; GPIIb/IIIa; C-terminal sequencing; Mass spectrometry; Posttranslational modification

1. INTRODUCTION

GPIIb and GPIIIa form a surface-oriented, Ca^{2+} -dependent heterodimer which serves as the fibrinogen receptor at the surface of activated platelets [1]. GPIIb (136.5 kDa) is made up of two chains, GPIIb α (114 kDa) and GPIIb β (22.5 kDa) [2], joined by a single disulphide bond [3] between α Cys-826 and β Cys-9 [4]. GPIIIa (91.5 kDa) [2] is a single-chain, highly disulphide-bonded protein [5]. The cDNA sequences of GPIIb- and GPIIIa-like glycoproteins from HEL, megakaryocytes and endothelial cells suggest that GPIIb α does not possess any transmembrane segment and, therefore, is fully extracellular, and that GPIIb β and GPIIIa each possess a single transmembrane segment and a short cytoplasmic tail [6–9], so that most of their mass is extracellular and involved in the recognition of adhesive proteins. The cytoplasmic domains of GPIIb β and/or GPIIIa would most likely be responsible for the association of the platelet fibrinogen receptor to the cytoskeleton of activated platelets [10,11]. Therefore, a detailed structural knowledge of the cytoplasmic moieties of GPIIb and

GPIIIa is necessary to understand the molecular steps of the platelet response to aggregation agonists involving the cytoplasmic domains of the GPIIb/IIIa complex. In the present work the cytoplasmic ends of the GPIIb/IIIa complex are characterized by isolation and amino acid sequence analysis of C-terminal fragments.

2. MATERIALS AND METHODS

2.1. Materials

TPCK-trypsin was from Sigma; porous glass beads (CPG-10, 200 mesh, 37.5 nm pore diameter) were from Corning. Chromatography columns and buffers were as previously described [3,5].

2.2. Methods

Preparation of human platelets, platelet plasma membranes, and the isolation of GPIIb, GPIIIa and CM-GPIIb β were described previously [3,5]. Fully reduced and alkylated GPIIIa was prepared by reduction of pure GPIIIa (5 mg/ml in 50 mM Tris-HCl, pH 8.0) with 1% (v/v) 2-mercaptoethanol (2 min, 100°C), and alkylation with 1.5 molar excess of iodoacetate over reducing agent.

Protein assay was performed according to [13]. Amino acid analyses were performed with a Biotronik amino acid analyzer after hydrolysis at 110°C in 6 N HCl for 24 h. N-terminal sequence analysis was carried out as described in [14].

Aminopropyl glass beads were prepared according to [15], and the aminopropyl side chains converted into isothiocyanate side chains according to [16]. Protein (5 nmol) was coupled to the derivatized glass beads (25 mg) in 200 μ l of 1% SDS, 0.1 M sodium bicarbonate, pH 9.0 at 45°C for 3 h, and the reaction stopped with a molar excess of *n*-propylamine over reactive side chains. The coupling yield was 80–90% as estimated by amino acid analysis.

C-terminal sequence determination was carried out according to [17], except that the hydrolysis was done in 0.2 M acetohydroxamate,

Correspondence address: J. Gonzalez-Rodriguez, Instituto de Química-Física, CSIC, c/Serrano, 119, 28006 Madrid, Spain

Abbreviations: GPIIb, glycoprotein IIb; GPIIIa, glycoprotein IIIa; CM-GPIIIa, CM-GPIIb β , fully reduced and carboxymethylated glycoprotein IIIa and IIb β , respectively; HEL, human erythroleukemic cell line

0.5 M sodium phosphate, pH 8.3 at 55°C for 30 min [18]. The extracted 2-thiohydantoin derivatives were analyzed by reverse-phase HPLC [17] using a Lichrospher 100 RP-18 (5 μ m) column (Merck, Darmstadt). Standard 2-thiohydantoin derivatives were prepared as described [19].

Isolation of the CNBr-degradation fragment containing the C-terminal segment of GPIIb β was performed as described [20]. Tryptic digestion of this fragment (10 mg/ml in 50 mM ammonium bicarbonate, 0.1% (v/v) N-ethylmorpholine, pH 8.0) was done at an enzyme/substrate ratio of 1:100 (w/w) for 3 h at 37°C. The tryptic peptides were separated by reverse-phase HPLC using a Vydac C4 (10 μ m, 30.0 nm) column, and acetonitrile gradient elution.

Mass spectra were recorded with a mass spectrometer HSQ 30 (Finnigan MAT, Bremen) equipped with an atom gun (Ion Tech Ltd, Teddington, England). Peptides were dissolved in acetonitrile/acetic acid/water (50:10:40, v/v/v) and mixed with glycerol [21]. Esterification of peptides was carried out by treating 10 nmol of freeze-dried peptide with 50 μ l of 1 M isopropanol in 12 N HCl overnight at room temperature.

3. RESULTS AND DISCUSSION

Fully reduced and carboxymethylated GPIIb β was cleaved with CNBr, and the peptide containing the C-

terminus of GPIIb β (β (117–137)) was isolated by reverse-phase HPLC as previously described [20]. This peptide was sequenced up to glycine 136, i.e. the penultimate residue. In order to identify the C-terminal residue of platelet GPIIb β , CM-GPIIb β was chemically sequenced from its C-terminus (see section 2). Two cleavage cycles were successfully effected, the amino acids recovered being glutamine and glycine, respectively (Fig. 1B). When the same chemical method for C-terminal sequencing was applied by us to known standard proteins, agreement with published results was obtained, e.g. for horse heart cytochrome c: glutamic acid and asparagine, for human serum albumin: leucine, glutamine and serine, and for whale sperm apomyoglobin: glycine and glutamic acid (data not shown). To confirm the result with GPIIb β the C-terminal CNBr-fragment β 117–137 was digested with trypsin, yielding two peptides, CR1 (β 125–137: NRPPLEEDDEEG(E/Q)) and CR2 (β 119–123), after reverse-phase HPLC separation (Fig. 2). The peptide CR1 (β 125–137) was analyzed by mass spectrometry




Fig. 1. HPLC analysis of the thiohydantoin-amino acid products of C-terminal sequential degradation of CM-GPIIb β and CM-GPIIIa. The standard thiohydantoin-amino acid derivatives (A) and material from the first two cycles of C-terminal sequential degradation of CM-GPIIb β (B) and CM-GPIIIa (C) were separated by HPLC on Lichrospher 100 RP 18 (5 μ m) (25 cm \times 0.46 cm), as described in section 2. Peaks are labelled using the one-letter abbreviations.




Fig. 2. Isolation of the tryptic digestion products of the CNBr-fragment CM-GPIIb β 117-137 by HPLC on Vydac C₄ (see section 2).

either underivatized or after esterification of the carboxyl group with isopropanol/HCl (see section 2). The molecular masses ($M+H^+$) obtained for the underivatized and the esterified β 125-137 peptide

(1528 and 1823, respectively) (Fig. 3) provided further evidence that the C-terminal amino acid residue of platelet GPIIb β is glutamine. However, glutamic acid, and not glutamine, was predicted by cDNA sequencing for GPIIb β in HEL and in megakaryocyte cells [7,12,22]. The most likely explanations for the discrepancy between the cDNA-predicted and the chemically established C-terminal residue for GPIIb β are either that there are cell-type specific copies of the exon coding for the C-terminal, or that the C-terminus of the GPIIb precursor is posttranslationally modified, as already observed in other proteins [23]. Recently, Prandini et al. [24] have sequenced the 3' end of the GPIIb gene from a genomic library, containing an exon encoding the 19 C-terminal amino acid residues of GPIIb and a 3' untranslated region; the sequence showed glutamic acid as the C-terminal residue. Moreover, the same authors showed that there is only one copy of the GPIIb gene per human genome. This indicates that the first explanation can be ruled out. The role of glutamine, instead of glutamic acid, if any, in the interaction of the GPIIb/IIIa complex with




Fig. 3. Fast atom bombardment mass spectrometry of the tryptic peptide CR1 (β 125-137) corresponding to the C-terminal end of GPIIb β , both unmodified (A) and esterified (B) material being analysed.

elements of the activated platelet cytoskeleton requires further investigation.

Chemical C-terminal amino acid sequence analysis of fully reduced and carboxymethylated GPIIIa was also performed (see section 2). Two degradation cycles were successfully carried out, the amino acids obtained being threonine and glycine, respectively (Fig. 1C). This sequence is identical to that predicted by cDNA analysis for GPIIIa from HEL and endothelial cells [6,8,9].

During recent years our laboratories have been engaged in the protein-chemical characterization of GPIIb/IIIa. Thus, peptides which correspond to more than 70% of the whole GPIIIa structure have been isolated and analyzed for amino acid and amino sugar composition as well as N-terminal sequence. So far no differences from the cDNA sequences deduced for GPIIIa from HEL and endothelial cells [6,8,9] have been observed, with the exception of the sequence at positions 623–627 initially published as EPYMT [6,9] and subsequently corrected to be GALHD [8], where our data are in accordance with the latter report. All results together strengthen the conclusion that the three different cell types, HEL, endothelial cells and platelets express the identical glycoprotein IIIa.

Acknowledgements: Mr G. Rivas is gratefully acknowledged for his help in the preparation of GPIIb and GPIIIa. We thank Mrs C. Martin de Loeches, Mrs G. Pinillos, Mrs H. Gross and Mrs B. Rinke for excellent technical assistance, and Dr D. Georgopoulos for helping in amino acid analysis. The authors wish to thank the Blood Banks of Centro Ramon y Cajal, La Paz and Doce de Octubre (Madrid) for providing us with outdated platelet concentrates. This work was supported by the DGICYT (PB 86-0629 and PM 88-0022) and German-Spanish Joint Research Programme (1989-1990) (AA-II).

REFERENCES

- [1] Phillips, D.R., Charo, I.F., Parise, L.V. and Fitzgerald, L.A. (1988) *Blood* 71, 831–843.
- [2] Usobiaga, P., Calvete, J.J., Saiz, J.L., Eirin, M.T. and Gonzalez-Rodriguez, J. (1987) *Eur. J. Biophys.* 14, 211–218.
- [3] Calvete, J.J. and Gonzalez-Rodriguez, J. (1986) *Biochem. J.* 240, 155–161.
- [4] Calvete, J.J., Alvarez, M.V., Rivas, G., Hew, C.-L., Henschen, A. and Gonzalez-Rodriguez, J. (1989) *Biochem. J.* 261, 551–560.
- [5] Eirin, M.T., Calvete, J.J. and Gonzalez-Rodriguez, J. (1986) *Biochem. J.* 240, 147–153.
- [6] Fitzgerald, L.A., Steiner, B., Rall, S.C. jr, Lo, S.S. and Phillips, D.R. (1987) *J. Biol. Chem.* 262, 3936–3939.
- [7] Poncz, M., Eisman, R., Heidenreich, R., Silver, S.M., Vilaire, G., Surrey, S., Schwartz, E. and Bennett, J.S. (1987) *J. Biol. Chem.* 262, 8476–8482.
- [8] Rosa, J.-P., Bray, P.F., Gayet, O., Johnston, G.I., Cook, R.G., Jackson, K.W., Shuman, M.A. and McEver, R.P. (1988) *Blood* 72, 593–600.
- [9] Zimrin, A.B., Eisman, R., Vilaire, G., Schwartz, E., Bennett, J.S. and Poncz, M. (1988) *J. Clin. Invest.* 81, 1470–1475.
- [10] Shattil, S.J. and Brass, L.F. (1987) *J. Biol. Chem.* 262, 992–1000.
- [11] Phillips, D.R., Jennings, L.K. and Edwards, H.H. (1980) *J. Cell Biol.* 86, 77–86.
- [12] Uzan, G., Frachet, P., Lajmanovich, A., Prandini, M.H., Denarier, E., Duperray, A., Loftus, J., Ginsberg, M., Plow, E. and Marguerie, G. (1988) *Eur. J. Biochem.* 171, 87–93.
- [13] Markwell, M.A.K., Haas, S.M., Bieber, L.L. and Tolbert, N.E. (1978) *Anal. Biochem.* 87, 206–210.
- [14] Edman, P. and Henschen, A. (1975) in: *Protein Sequence Determination* (Needleman, S.B. ed.) pp.232–279, Springer, Berlin.
- [15] Robinson, P.J., Dunnill, P. and Lilly, M.D. (1971) *Biochim. Biophys. Acta* 242, 659–661.
- [16] Wachter, E., Machleidt, W., Hafner, H. and Otto, J. (1973) *FEBS Lett.* 35, 97–102.
- [17] Hawke, D.H., Lahm, H.W., Shively, J.E. and Todd, R.W. (1987) *Anal. Biochem.* 166, 298–307.
- [18] Stark, G.R. (1968) *Biochemistry* 7, 1796–1807.
- [19] Stark, G.R. (1972) *Methods Enzymol.* 25, 369–384.
- [20] Calvete, J.J., Henschen, A. and Gonzalez-Rodriguez, J. (1989) *Biochem. J.* 261, 551–560.
- [21] Naylor, S., Finders, A.F., Gibson, B.M. and Williams, D.H. (1986) *J. Am. Chem. Soc.* 108, 6359–6363.
- [22] Bray, P.F., Rosa, J.-P., Johnston, G.I., Shiu, D.T., Cook, R.G., Lau, C., Kan, Y.W., McEver, R.P. and Shuman, M.A. (1987) *J. Clin. Invest.* 80, 1812–1817.
- [23] Wold, F. (1981) *Annu. Rev. Biochem.* 50, 783–814.
- [24] Prandini, M.H., Denarier, E., Frachet, P., Uzan, G. and Marguerie, G. (1988) *Biochem. Biophys. Res. Commun.* 156, 595–601.